peginterferon beta-1a

High Adherence to Rebif Seen With RebiSmart Use, Chats With Doctor

Regular feedback from doctors about dosing data and health status is associated with high and sustained treatment adherence to RebifĀ (interferon beta-1a) amongĀ multiple sclerosis (MS)Ā patients using the RebiSmart autoinjector, a two-year observational study shows. This study’s level of treatment adherence ā€” 97.9% ā€” was comparable or superior to the…

FDA Approves Plegridy as Intramuscular Injection for Relapsing MS

The U.S. Food and Drug Administration (FDA) has approved an intramuscular injectionĀ formulation of Plegridy (peginterferon beta-1a) to treat people with relapsing forms of multiple sclerosis (MS). This formulation, for injection directly into muscle, is what is typically used to deliver the flu shot. According to Biogen, Plegridy’s…

Plegridy as Intramuscular Injection for RRMS Approved in Europe

The European Commission (EC) has approved a new, intramuscular formulation of Plegridy (peginterferon beta-1a) to treat people with relapsing-remitting multiple sclerosis (RRMS). This new mode of administration ā€” in which Plegridy is directly injected into the muscle, rather than under the skin (subcutaneously) ā€” does…

NICE Approves Plegridy as RRMS Treatment Offered by NHS England

The National Institute for Health Care and Excellence (NICE) in the U.K. issued its final decision, approving the inclusion of Plegridy (peginterferon beta-1a) to treatĀ relapsing-remitting multiple sclerosis (RRMS) in England within the National Health Service (NHS). This decision follows a cost-effectiveness review done in May 2018,…

#ECTRIMS2019 ā€” Biogen Presents New Real-world Data Demonstrating Clinical Benefits of Tysabri, Plegridy, and Avonex

Biogen is presenting new data highlighting the potential clinical benefits of Tysabri (natalizumab), Plegridy (peginterferon beta-1a), and Avonex (interferon beta-1a) for the treatment of specific groups of individuals with multiple sclerosis (MS), including pregnant women and patients with relapsing forms of the disease. The new…

NHS Wales Approves Biogen’s Plegridy for Relapsing Remitting MS

Relapsing remitting multiple sclerosis (RRMS) treatment PlegridyĀ (peg interferon beta-1a) by Biogen Idec, has just received Welsh NHS approval, which should make it available to patients by late October 2015. The decisionĀ follows NHS Scotland’s approval earlier this year, however, theĀ biweekly interferon beta shot has yet to be madeĀ available in England’s NICE…

New Relapsing-Remitting Multiple Sclerosis Drug Approved By FDA

Biogen Idec, a biotechnology company focused on developing innovative therapies for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders, has announced that the U.S. Food and Drug Administration (FDA) has approved PLEGRIDYTMĀ (peginterferon beta-1a), a new treatment for people with relapsing forms of multiple sclerosis…